Clinical Trial of Telenursing for Monitoring Supportive Care Needs in Patients With Lung Cancer and Melanoma Candidates for the First Prescription of Targeted Therapies

Launched by REGINA ELENA CANCER INSTITUTE · Feb 2, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how effective a new method called Telenursing is for helping patients with lung cancer and melanoma who are starting targeted therapies. Telenursing involves using technology, like video calls or apps, to monitor patients' supportive care needs and provide assistance from a distance. The trial will compare two groups of patients: one group will receive standard care, while the other group will receive additional support through Telenursing. The goal is to see if Telenursing can improve the overall comfort and support patients feel during their treatment.

To be eligible for this trial, participants must be between 18 and 75 years old and have lung cancer or melanoma, specifically those who haven't started targeted therapies yet. They should be able to understand and speak Italian and have access to a computer or tablet with internet. Patients with other types of cancer, those already receiving targeted therapies, or anyone with cognitive or psychiatric issues that might affect their participation will not be eligible. If you join the trial, you can expect regular check-ins through Telenursing or standard care, and your experience will help researchers understand better ways to support patients during treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • aged between 18 and 75;
• • patients suffering from lung cancer and melanoma candidates for the first prescription with Targeted Therapies in exclusive treatment;
• • patients able to understand, speak Italian and join the study by signing of paper informed consent;
• • possibility of accessing and using the information technologies adopted in trial through a PC/tablet and personal internet connection;
• • patients willing to comply with study procedures.
• Exclusion Criteria:
• • patients not suffering from lung cancer or melanoma;
• • patients already treated or currently being treated with Targeted Therapies, or other treatment (chemotherapy and/or radiotherapy and/or exclusive palliative care);
• • patients with cognitive problems, psychiatric disorders and poor compliance who could interfere with study participation.